1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Graded cardiac response criteria for AL amyloidosis: The impact of depth of cardiac response on survival
    Meeting Abstract

    Muchtar, E.; Dispenzieri, A.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelken, K.; Hegenbart, U.; Kumar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Graded renal response criteria for light chain (AL) amyloidosis
    Meeting Abstract

    Muchtar, E.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelken, K.; Hegenbart, U.; Dispenzieri, A.; Kumar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)
    Meeting Abstract

    Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R (2)) versus rituximab-chemotherapy followed by rituximab maintenance
    Meeting Abstract

    Morschhauser, F.; Nastoupil, L.; Feugier, P.; De Colella, J. M. S.; Tilly, H.; Palomba, M. L.; Bachy, E.; Fruchart, C.; Libby, E.; Casasnovas, R. O.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks
    Meeting Abstract

    Mauro, M. J.; Minami, Y.; Rea, D.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J. F.; Cortes, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • End of treatment peripheral blood TCR evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Jacobsen, E. D.; Fehniger, T. A.; Kahl, B. S.; Bartlett, N. L.; Cashen, A. F.; Ghobadi, A.; Reagan, B.; Fischer, A.; Moskowitz, A. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post-transplant inotuzumab ozogamicin for acute lymphoblastic leukemia
    Meeting Abstract

    Metheny, L. 3rd; Sobecks, R. M.; Cho, C.; Caimi, P. F.; Majhail, N. S.; Otegbeye, F.; Boughan, K. M.; Cooper, B. W.; Galloway, E.; Gallogly, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clonotype-immunophenotype relationships in TET2 and IDH-mutant myeloid transformation
    Meeting Abstract

    Miles, L. A.; Bowman, R. L.; Delgaudio, N.; Robinson, T.; Carroll, M. P.; Meyer, S. E.; Levine, R. L.
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Duration of objective responses for patients with indolent non-Hodgkin lymphoma discontinuing treatment before progression: Analysis from the phase III CHRONOS-3 trial comparing copanlisib plus rituximab with placebo plus rituximab
    Meeting Abstract

    Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yañez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
    Blood (2021)

    Fulltext@MSK | Save